The human gene for theenkephalins was isolated and its sequence described in 1982.[4]
The human gene fordynorphins (originally called the "Enkephalin B" gene because of sequence similarity to the enkephalin gene) was isolated and its sequence described in 1983.[5]
The PNOC gene encodingprepronociceptin, which is cleaved intonociceptin and potentially two additional neuropeptides.[1]
†This symbol next to a receptor indicates that the corresponding peptide is a principal endogenous agonist of the receptor in humans. ‡This symbol next to a receptor indicates that the corresponding peptide is the endogenous ligand with the highest knownpotency for the receptor in humans.
^Stefano GB, Ptáček R, Kuželová H, Kream RM (2012)."Endogenous morphine: up-to-date review 2011"(PDF).Folia Biol. (Praha).58 (2):49–56.doi:10.14712/fb2012058020049.PMID22578954.Positive evolutionary pressure has apparently preserved the ability to synthesize chemically authentic morphine, albeit in homeopathic concentrations, throughout animal phyla. ... The apparently serendipitous finding of an opiate alkaloid-sensitive, opioid peptide-insensitive, µ3 opiate receptor subtype expressed by invertebrate immunocytes, human blood monocytes, macrophage cell lines, and human blood granulocytes provided compelling validating evidence for an autonomous role of endogenous morphine as a biologically important cellular signalling molecule (Stefano et al., 1993; Cruciani et al., 1994; Stefano and Scharrer, 1994; Makman et al., 1995). ... Human white blood cells have the ability to make and release morphine
^ab"μ receptor".IUPHAR/BPS Guide to PHARMACOLOGY. International Union of Basic and Clinical Pharmacology. 15 March 2017. Retrieved28 December 2017.Comments: β-Endorphin is the highest potency endogenous ligand ... Morphine occurs endogenously (Poeaknapo et. al. 2004) ... Principal endogenous agonists (Human) [are] β-endorphin (POMC, P01189), [Met]enkephalin (PENK, P01210), [Leu]enkephalin (PENK, P01210), citing:
^abcdefghiToll L, Caló G, Cox BM, Chavkin C, Christie MJ, Civelli O, Connor M, Devi LA, Evans C, Henderson G, Höllt V, Kieffer B, Kitchen I, Kreek MJ, Liu-Chen LY, Meunier JC, Portoghese PS, Shippenberg TS, Simon EJ, Traynor JR, Ueda H, Wong YH (10 August 2015)."Opioid receptors: Introduction".IUPHAR/BPS Guide to PHARMACOLOGY. International Union of Basic and Clinical Pharmacology. Retrieved20 October 2017.
^abc"δ receptor".IUPHAR/BPS Guide to PHARMACOLOGY. International Union of Basic and Clinical Pharmacology. 15 May 2017. Retrieved28 December 2017.Principal endogenous agonists (Human) [are] β-endorphin (POMC, P01189), [Leu]enkephalin (PENK, P01210), [Met]enkephalin (PENK, P01210)
^ab"κ receptor".IUPHAR/BPS Guide to PHARMACOLOGY. International Union of Basic and Clinical Pharmacology. 21 February 2017. Retrieved28 December 2017.Comments: Dynorphin A and big dynorphin are the highest potency endogenous ligands ... Principal endogenous agonists (Human) [are] big dynorphin (PDYN, P01213), dynorphin A (PDYN, P01213)
^"Dynorphin A 1–8".HMDB Version 4.0. Human Metabolome Database. 27 September 2017. Retrieved20 October 2017.Dynorphin A (1–8) is a fraction of Dynorphin A with only Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile peptide chain.
^"Big dynorphin: Biological activity".IUPHAR/BPS Guide to PHARMACOLOGY. International Union of Basic and Clinical Pharmacology. Retrieved20 October 2017.Principal endogenous agonists at κ receptor.
^"Big dynorphin: Structure – Peptide Sequence".IUPHAR/BPS Guide to PHARMACOLOGY. International Union of Basic and Clinical Pharmacology. Retrieved20 October 2017.Peptide sequence YGGFLRRIRPKLKWDNQKRYGGFLRRQFKVVT
^"Dynorphin B (1-29)".PubChem Compound. United States National Library of Medicine – National Center for Biotechnology Information. 23 December 2017. Retrieved28 December 2017.
^Suda M, Nakao K, Yoshimasa T, Sakamoto M, Morii N, Ikeda Y, Yanaihara C, Yanaihara N, Numa S, Imura H (September 1984). "Human leumorphin is a potent, kappa opioid receptor agonist".Neuroscience Letters.50 (1–3):49–52.doi:10.1016/0304-3940(84)90460-9.PMID6149506.S2CID42419724.
^Inenaga K, Nagatomo T, Nakao K, Yanaihara N, Yamashita H (January 1994). "Kappa-selective agonists decrease postsynaptic potentials and calcium components of action potentials in the supraoptic nucleus of rat hypothalamus in vitro".Neuroscience.58 (2):331–340.doi:10.1016/0306-4522(94)90039-6.PMID7908725.S2CID24631286.
^"NOP receptor".IUPHAR/BPS Guide to PHARMACOLOGY. International Union of Basic and Clinical Pharmacology. 18 August 2017. Retrieved28 December 2017.Natural/Endogenous Ligands nociceptin/orphanin FQ